In 2020, the sales revenue of Hengrui anti-tumor products reached 65.438+05.268 billion yuan, accounting for 55.05% of the total revenue and contributing 58.45% of the profits, both of which were much higher than those of anesthesia and contrast agent business.
After years of research and development, Hengrui has a variety of innovative anti-tumor drugs, including karelizumab, apatinib, tiofepristine, Pyrrolidine, fluzopali and darsilli.
Hengrui has abundant R&D channels in the field of cancer, and it is also widely distributed in autoimmune diseases, pain management, cardiovascular diseases, metabolic diseases, diabetes and infectious diseases. With the continuous investment of the company, Hengrui's innovative research and development has been steadily advanced. Now eight innovative drugs have been approved for listing, and innovation has entered the harvest period. In June this year alone, Hengrui has been approved to market five kinds of drugs, including azishatan tablets, bevacizumab injection and the self-developed innovative drug Hettrepaethanolamine tablets. At the same time, two innovative drugs, karelizumab and fluzopali, each had a new indication, and six drugs were allowed to enter different clinical trial stages. At present, Hengrui * * has more than 40 innovative drugs at different clinical stages.